Drug Trial Radar · NCT06254326
ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Sep 19, 2024
Primary completion
Dec 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- University of FloridaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Oligo Nation, Inc
- First posted
- Feb 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will enroll 6 DLT evaluable subjects (up to 12 patients total) where we will evaluate feasibility and safety of adoptive cellular therapy combined with IDH1/2 inhibitors in patients with recurrent or progressive oligodendroglioma WHO grade 2 and WHO grade 3.
Conditions
- Recurrent Oligodendroglioma
- Progressive Oligodendroglioma
Interventions
TTRNA-DC vaccines with GM-CSFBiological
Participants will receive up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment
Autologous Hematopoietic Stem cells (HSCs)Biological
Participants will receive a single infusion of autologous CD34+ HSCs
TTRNA-xALTBiological
Participants will receive a single infusion of ex vivo expanded tumor-reactive T cells
Td vaccineDrug
All patients will receive a full Td booster IM vaccine 4-24 hours prior to Vaccine #1 and vaccine site pretreatment with a one-fifth dose of Td intradermally, at the site of planned vaccine, 4-24 hours prior to vaccines #3, #5, #7 and #9.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prevalence of enrolled subject who receive qualified immunotherapy investigational product.Time frame: enrollment up to 9 months
- Incidence of investigational treatment related severe toxicity (Dose-limiting toxicity event) assessed during the period beginning with administration of ex vivo expanded TTRNA T cells through 6 weeks post infusion.Time frame: enrollment to completion of DLT window; up to 9 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Florida Health Shands Hospital
Gainesville, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.